Uceris Aerosol, Foam
NDC 65649-651
Product Information
Uceris (budesonide) is a NDA-approved product labeled by Salix Pharmaceuticals, Inc.. This medication is used to treat symptoms of a certain bowel disease (ulcerative colitis). It is supplied as a white aerosol, foam for rectal administration. This product entry covers the primary NDC 65649-651 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 65649-651?
What are the uses of this product?
What are Active Ingredients of this product?
- BUDESONIDE 2 mg/1 - A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- BUDESONIDE (UNII: Q3OKS62Q6X)
- BUDESONIDE (UNII: Q3OKS62Q6X) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- CETYL ALCOHOL (UNII: 936JST6JCN)
- EDETATE DISODIUM (UNII: 7FLD91C86K)
- CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1596778 - UCERIS 2 MG/ACTUAT Rectal Foam, 14 ACTUAT
- RxCUI: 1596778 - 14 ACTUAT budesonide 2 MG/ACTUAT Rectal Foam [Uceris]
- RxCUI: 1596778 - Uceris 2 MG/ACTUAT Rectal Foam, 14 ACTUAT
- RxCUI: 1596779 - budesonide 2 MG/ACTUAT Rectal Foam, 14 ACTUAT
- RxCUI: 1596779 - 14 ACTUAT budesonide 2 MG/ACTUAT Rectal Foam
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.